Zura Bio Limited Stock Performance
| ZURA Stock | 3.00 0.01 0.33% |
The firm maintains a market beta of 2.13, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zura Bio will likely underperform. At this point, Zura Bio Limited has a negative expected return of -0.37%. Please make sure to check out Zura Bio's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Zura Bio Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zura Bio Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.66) | Five Day Return 0.34 | Year To Date Return (31.95) | Ten Year Return (59.12) | All Time Return (59.12) |
1 | Disposition of 51728 shares by Sidhu Someit of Zura Bio at 3.87 subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 3800000 shares by Thiara Parvinder of Zura Bio at 2.7 subject to Rule 16b-3 | 09/11/2024 |
3 | Acquisition by Nistala Kiran of 350000 shares of Zura Bio at 3.98 subject to Rule 16b-3 | 09/20/2024 |
4 | Armistice Capital LLC Buys 876,000 Shares of Zura Bio Limited - MarketBeat | 09/26/2024 |
5 | Private equity firms among Zura Bio Limiteds largest shareholders, saw gain in holdings value after stock jumped 14 percent last week | 10/17/2024 |
6 | Zura Bio to Participate in Two Upcoming Investor Conferences in November | 10/30/2024 |
7 | Leerink Partners Initiates Coverage of Zura Bio with Outperform Recommendation - MSN | 11/04/2024 |
8 | Zura Bio GAAP EPS of -0.26 misses by 0.13 | 11/07/2024 |
9 | Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis | 11/14/2024 |
10 | HC Wainwright Reaffirms Neutral Rating for Zura Bio | 11/19/2024 |
11 | JATT Acquisition Reports Regulation FD Disclosure | 11/25/2024 |
| Begin Period Cash Flow | 1.6 M |
Zura |
Zura Bio Relative Risk vs. Return Landscape
If you would invest 413.00 in Zura Bio Limited on August 30, 2024 and sell it today you would lose (113.00) from holding Zura Bio Limited or give up 27.36% of portfolio value over 90 days. Zura Bio Limited is currently does not generate positive expected returns and assumes 5.1208% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Zura, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zura Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zura Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zura Bio Limited, and traders can use it to determine the average amount a Zura Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.073
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZURA |
Estimated Market Risk
| 5.12 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zura Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zura Bio by adding Zura Bio to a well-diversified portfolio.
Zura Bio Fundamentals Growth
Zura Stock prices reflect investors' perceptions of the future prospects and financial health of Zura Bio, and Zura Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zura Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 196.88 M | ||||
| Shares Outstanding | 63.77 M | ||||
| Price To Book | 1.28 X | ||||
| EBITDA | (60.56 M) | ||||
| Net Income | (60.56 M) | ||||
| Total Debt | 21.29 M | ||||
| Book Value Per Share | 2.34 X | ||||
| Cash Flow From Operations | (15.05 M) | ||||
| Earnings Per Share | 0.57 X | ||||
| Market Capitalization | 295.78 M | ||||
| Total Asset | 100.84 M | ||||
| Retained Earnings | (103.49 M) | ||||
| Working Capital | 80.54 M | ||||
About Zura Bio Performance
By analyzing Zura Bio's fundamental ratios, stakeholders can gain valuable insights into Zura Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zura Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zura Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (1.02) | (0.97) |
Things to note about Zura Bio Limited performance evaluation
Checking the ongoing alerts about Zura Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zura Bio Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zura Bio Limited generated a negative expected return over the last 90 days | |
| Zura Bio Limited has high historical volatility and very poor performance | |
| Net Loss for the year was (60.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zura Bio generates negative cash flow from operations | |
| Zura Bio Limited has a poor financial position based on the latest SEC disclosures | |
| About 32.0% of the company outstanding shares are owned by insiders | |
| Latest headline from thelincolnianonline.com: JATT Acquisition Reports Regulation FD Disclosure |
- Analyzing Zura Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zura Bio's stock is overvalued or undervalued compared to its peers.
- Examining Zura Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zura Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zura Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zura Bio's stock. These opinions can provide insight into Zura Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zura Stock analysis
When running Zura Bio's price analysis, check to measure Zura Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zura Bio is operating at the current time. Most of Zura Bio's value examination focuses on studying past and present price action to predict the probability of Zura Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zura Bio's price. Additionally, you may evaluate how the addition of Zura Bio to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |